Patents by Inventor Prasun K. Chakravarty

Prasun K. Chakravarty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
    Patent number: 5780481
    Abstract: The invention is a method for inhibiting activation of the human A3 adenosine receptor with adenosine, by treating the receptor a compound of the formula ##STR1## to treat asthma.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marlene A. Jacobson, Richard Norton, Prasun K. Chakravarty
  • Phenoxyphenylacetic acid derivatives
    Patent number: 5767310
    Abstract: Phenoxyphenylacetic acids and derivatives of general structural formula (I) have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.
    Type: Grant
    Filed: November 8, 1995
    Date of Patent: June 16, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Scott W. Bagley, Theodore P. Broten, Prasun K. Chakravarty, Daljit S. Dhanoa, Kenneth J. Fitch, William J. Greenlee, Nancy Jo Kevin, Douglas J. Pettibone, Ralph A. Rivero, James R. Tata, Thomas F. Walsh, David L. Williams, Jr.
  • Phenoxyphenylacetic acid derivatives
    Patent number: 5668176
    Abstract: Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: September 16, 1997
    Assignee: Merck & Co. Inc.
    Inventors: Scott W. Bagley, Theodore P. Broten, Prasun K. Chakravarty, Daljit S. Dhanoa, Kenneth J. Fitch, William J. Greenlee, Nancy Jo Kevin, Gerard R. Kieczykowski, Douglas J. Pettibone, James R. Tata, Ralph A. Rivero, Thomas F. Walsh, David L. Williams, Jr., Jay M. Matthews, Richard B. Toupence
  • Substituted phthalazinones as neurotensin antagonists
    Patent number: 5668279
    Abstract: Novel substituted phthalazinones of the formula (I) ##STR1## are useful as neurotensin antagonists.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: September 16, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Elizabeth M. Naylor, Anna Chen
  • Biphenyl compounds useful or endothelin antagonists
    Patent number: 5565485
    Abstract: Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: October 15, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Scott W. Bagley, Theodore P. Broten, Prasun K. Chakravarty, Daljit S. Dhanoa, Kenneth J. Fitch, William J. Greenlee, Nancy J. Kevin, Douglas J. Pettibone, Ralph A. Rivero, Thomas F. Walsh, David L. Williams, Jr., Richard B. Toupence, Jay M. Matthews
  • 3-substituted piperidines promote release of growth hormone
    Patent number: 5559128
    Abstract: The present invention is directed to certain novel compounds identified as 3-substituted piperidines of the general structural formula: ##STR1## wherein R.sup.1, R.sup.1a, R.sup.2a, R.sup.4, R.sup.5, A, X, and Y are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing these compounds as the active ingredient thereof are also disclosed.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: September 24, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Ravi Nargund, Robert W. Marquis, Arthur A. Patchett, Lihu Yang
  • Substituted biphenylmethylimidazopyridines
    Patent number: 5554625
    Abstract: Biphenylmethylimidazopyridines of the structure (I) are angiotensin (II) antagonists and therefore useful in the treatment of hypertension and related cardiovascular disorders and ocular hypertension.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: September 10, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Ralph A. Rivero, Prasun K. Chakravarty, William J. Greenlee, Nancy J. Kevin, Nathan B. Mantlo
  • Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists
    Patent number: 5441959
    Abstract: Novel substituted quinazolinones of the formula (I) are useful as angiotensin II antagonists.
    Type: Grant
    Filed: August 18, 1993
    Date of Patent: August 15, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Stephen E. de Laszlo, Tomasz W. Glinka, William J. Greenlee, Nathan B. Mantlo, Arthur A. Patchett
  • Substituted 1,2,4-triazolin-3-one compounds bearing acidic functional groups as balanced angiotensin II antagonists
    Patent number: 5436259
    Abstract: Novel substituted 1,2,4-triazolin-3-ones of the formula (I) are useful as angiotensin II antagonists.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: July 25, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Prasun K. Chakravarty, Linda L. Chang
  • Heterocyclic compounds bearing acidic functional groups as angiotensin II antagonists
    Patent number: 5412097
    Abstract: Heterocyclic compounds of structural formula: ##STR1## wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.
    Type: Grant
    Filed: September 2, 1992
    Date of Patent: May 2, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, William J. Greenlee, Dooseop Kim, Nathan B. Mantlo, Arthur A. Patchett, Ralph A. Rivero
  • Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
    Patent number: 5411980
    Abstract: There are disclosed new substituted triazolinone, triazolinethione, and triazolinimine compounds which are useful as angiotensin II antagonists. These compounds have the general formula: ##STR1## wherein G is R.sup.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: May 2, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Linda L. Chang, Malcolm MacCoss, Prasun K. Chakravarty, William J. Greenlee, Arthur A. Patchett, Kelly Flanagan
  • Quinazolinones substituted with phenoxyphenylacetic acid derivatives
    Patent number: 5401745
    Abstract: Phenoxyphenylacetic acids and derivatives of general structural formula I ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebal and cardiac ischemia, myocardial infarction, inflammatory diseases, Raynaud's disease, and endotoxic shock, and asthma.
    Type: Grant
    Filed: March 19, 1993
    Date of Patent: March 28, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Scott W. Bagley, Prasun K. Chakravarty, Anna Chen, Daljit S. Dhanoa, Kenneth J. Fitch, William J. Greenlee, Elizabeth M. Naylor, James R. Tata, Thomas F. Walsh, David L. Williams, Jr.
  • Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
    Patent number: 5391566
    Abstract: Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, inflammatory diseases including Raynaud's disease and asthma.
    Type: Grant
    Filed: July 20, 1993
    Date of Patent: February 21, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Elizabeth M. Naylor, James R. Tata, Thomas F. Walsh
  • Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists
    Patent number: 5389660
    Abstract: There are disclosed new substituted imidazo-fused 5-membered ring heterocyclic compounds and derivatives thereof which are useful as angiotensin II antagonists.
    Type: Grant
    Filed: October 7, 1992
    Date of Patent: February 14, 1995
    Assignee: Merck & Co., Inc.
    Inventors: William J. Greenlee, David B. R. Johnston, Malcolm MacCoss, Nathan B. Mantlo, Arthur A. Patchett, Prasun K. Chakravarty, Thomas F. Walsh
  • Disubstituted 6-aminoquinazolinones
    Patent number: 5385894
    Abstract: Novel disubstituted 6-aminoquinazolinones of the Formula (I), are useful as angiotensin II antagonists: ##STR1##
    Type: Grant
    Filed: April 4, 1994
    Date of Patent: January 31, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Stephen E. de Laszlo, Tomasz W. Glinka, William J. Greenlee, Prasun K. Chakravarty, Arthur A. Patchett
  • Substituted triazoles as angiotensin II antagonists
    Patent number: 5336778
    Abstract: Novel substituted triazoles of the formula (I), which are useful as angiotensin II antagonists, are disclosed.
    Type: Grant
    Filed: June 22, 1992
    Date of Patent: August 9, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Christine L. Cantone, Linda L. Chang, Malcolm Maccoss, Prasun K. Chakravarty, William J. Greenlee, Arthur A. Patchett, Thomas F. Walsh
  • Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
    Patent number: 5334598
    Abstract: Phenoxyphenylacetic acids and derivatives of general structural formula I have endothelin ##STR1## antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, congestive heart failure, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, inflammatory diseases, Raynaud's disease, and endotoxic shock, and asthma.
    Type: Grant
    Filed: March 19, 1993
    Date of Patent: August 2, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Scott W. Bagley, Prasun K. Chakravarty, Anna Chen, Daljit S. Dhanoa, Kenneth J. Fitch, William J. Greenlee, Elizabeth M. Naylor, Thomas F. Walsh, David L. Williams, Jr.
  • Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
    Patent number: 5332744
    Abstract: Substituted Imidazo-fused 6-membered heterocycles of structural formula: ##STR1## wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.
    Type: Grant
    Filed: May 4, 1990
    Date of Patent: July 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, William J. Greenlee, Nathan B. Mantlo, Arthur A. Patchett, Thomas F. Walsh
  • Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
    Patent number: 5330987
    Abstract: Novel substituted pyridopyrimidinones of formula (I), which are useful as angiotensin II antagonists, are disclosed.
    Type: Grant
    Filed: June 4, 1992
    Date of Patent: July 19, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Eric E. Allen, Prasun K. Chakravarty, Stephen E. de Laszlo, William J. Greenlee, Arthur A. Patchett, Thomas F. Walsh
  • Substituted 1,2,4-triazoles bearing acidic functional groups as angiotensin II antagonists
    Patent number: 5281614
    Abstract: Novel substituted triazolinone, triazolinethione, and triazolinimine compounds of the formula I are useful as angiotensin II antagonists.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: January 25, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Prasun K. Chakravarty, Linda L. Chang, William J. Greenlee, Dooseop Kim, Nathan B. Mantlo, Arthur A. Patchett